Home » Stocks » ETTX

Entasis Therapeutics Holdings Inc. (ETTX)

Stock Price: $1.98 USD 0.06 (3.13%)
Updated Apr 22, 2021 4:00 PM EDT - Market closed
Pre-market: $2.03 +0.05 (2.53%) Apr 23, 7:00 AM
Market Cap 71.64M
Revenue (ttm) n/a
Net Income (ttm) -50.50M
Shares Out 36.64M
EPS (ttm) -2.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 22
Last Price $1.98
Previous Close $1.92
Change ($) 0.06
Change (%) 3.13%
Day's Open 1.92
Day's Range 1.89 - 2.03
Day's Volume 108,785
52-Week Range 1.58 - 4.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

– Phase 3 ATTACK registration trial more than three-quarters complete – – ATTACK topline data readout expected second half of 2021 – – Zoliflodacin Phase 3 trial adds clinical trial sites, continues enr...

1 month ago - GlobeNewsWire

WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibact...

2 months ago - GlobeNewsWire

WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibact...

3 months ago - GlobeNewsWire

WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibact...

5 months ago - GlobeNewsWire

WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibact...

5 months ago - GlobeNewsWire

WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibact...

6 months ago - GlobeNewsWire

WALTHAM, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antib...

7 months ago - GlobeNewsWire

Proceeds to support the ongoing ATTACK Phase 3 registration clinical trial Proceeds to support the ongoing ATTACK Phase 3 registration clinical trial

7 months ago - GlobeNewsWire

WALTHAM, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antiba...

8 months ago - GlobeNewsWire

Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

WALTHAM, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antiba...

9 months ago - GlobeNewsWire

WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antiba...

10 months ago - GlobeNewsWire

WALTHAM, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of ...

10 months ago - GlobeNewsWire

Wall Street sell-side analysts are positive about Ekso Bionics Holdings Inc (NASDAQ:EKSO) and Entasis Therapeutics Holdings Inc (NASDAQ:ETTX), even though their holdings have lost more than 59% over the...

Other stocks mentioned: EKSO
11 months ago - GuruFocus

WALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of...

1 year ago - GlobeNewsWire

CEO Dr. Manos Perros participated in Industry Panel today CEO Dr. Manos Perros participated in Industry Panel today

1 year ago - GlobeNewsWire

GENEVA and WALTHAM, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- The Global Antibiotic Research and Development Partnership (GARDP), a not for profit organization developing new treatments for drug resis...

1 year ago - GlobeNewsWire

WALTHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antib...

1 year ago - GlobeNewsWire

Entasis Therapeutics Holdings Inc. (ETTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 years ago - Zacks Investment Research

About ETTX

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinic... [Read more...]

Industry
Biotechnology
IPO Date
Sep 26, 2018
Stock Exchange
NASDAQ
Ticker Symbol
ETTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for ETTX stock is "Buy." The 12-month stock price forecast is 6.29, which is an increase of 217.68% from the latest price.

Price Target
$6.29
(217.68% upside)
Analyst Consensus: Buy